What is the recommended treatment plan for a patient with hypercholesterolemia (high cholesterol) or at high risk of cardiovascular events, considering Praluent (alirocumab) as a potential option?

Praluent (Alirocumab) Treatment Recommendations

Primary Indication and FDA-Approved Uses

Praluent (alirocumab) is FDA-approved to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease, and as adjunct therapy to reduce LDL-C in patients with primary hyperlipidemia including familial hypercholesterolemia. 1

---

Treatment Algorithm for Praluent Initiation

Step 1: Identify Appropriate Candidates

Very High-Risk Patients with Established ASCVD:

• Patients with documented atherosclerotic cardiovascular disease (prior MI, stroke, ACS, or coronary revascularization) who remain at very high risk 2
• Target LDL-C goal: <55 mg/dL (<1.4 mmol/L) with ≥50% reduction from baseline 2

Patients with Familial Hypercholesterolemia:

• Adults with heterozygous or homozygous familial hypercholesterolemia 1
• Pediatric patients aged 8 years and older with heterozygous FH 1

Step 2: Verify Prior Treatment Requirements

Before initiating Praluent, patients MUST have:

• Been on maximally tolerated statin therapy (preferably high-intensity) for at least 4 weeks 2
• Added ezetimibe if LDL-C targets not achieved with statin alone 2
• Current LDL-C ≥70 mg/dL despite maximal statin ± ezetimibe therapy 2

Alternative pathway for statin-intolerant patients:

• Documented intolerance to at least three different statins at appropriate doses 2
• Elevated LDL-C levels despite other lipid-lowering therapies 3, 4

Step 3: Risk Stratification for Treatment Thresholds

Patients with additional high-risk features warrant lower LDL-C thresholds for PCSK9 inhibitor initiation: 2

• Concomitant familial hypercholesterolemia
• Diabetes mellitus with target organ damage
• Severe or extensive ASCVD
• Rapid ASCVD progression (repeated ACS, unplanned revascularizations, or recurrent stroke within 5 years)
• Lipoprotein(a) >50 mg/dL
• Marked hypertension

For these highest-risk patients, consider Praluent when LDL-C remains substantially elevated (>70-100 mg/dL) despite maximal oral therapy. 2

---

Dosing and Administration

Standard dosing regimen:

• Initial dose: 75 mg subcutaneously every 2 weeks 1, 5
• If additional LDL-C lowering needed: increase to 150 mg every 2 weeks 1, 5, 3
• This tailored approach allows dose adjustment based on individual LDL-C response 6

Expected efficacy:

• LDL-C reduction: 50-60% when added to background therapy 2, 5, 3
• Additional benefits: 25-30% reduction in Lp(a), favorable effects on non-HDL-C and apolipoprotein B 3, 7

---

Cardiovascular Outcomes Evidence

The ODYSSEY OUTCOMES trial demonstrated that alirocumab reduces major adverse cardiovascular events by approximately 15% in patients with recent acute coronary syndrome on statin therapy. 2 This relative risk reduction translates to meaningful absolute benefit in very high-risk populations, particularly those with baseline LDL-C >100 mg/dL (>2.6 mmol/L) 2.

---

Clinical Considerations and Common Pitfalls

Do NOT use Praluent for:

• Primary treatment of hypertriglyceridemia (not indicated; use fibrates or omega-3 fatty acids instead) 8
• Patients at low or moderate cardiovascular risk (burden outweighs benefit) 2
• Women of childbearing potential without adequate contraception (applies to all lipid-lowering therapy) 2

Safety profile:

• Generally well-tolerated with no increase in muscle-related adverse events compared to placebo 3, 4
• Very low LDL-C levels (<20 mg/dL) achieved with PCSK9 inhibitors appear safe in clinical trials 2
• No detrimental effects on steroid hormone production, bile acid circulation, or neuronal function 2

Cost-effectiveness considerations:

• Prioritize use in patients with substantially elevated LDL-C despite maximal oral therapy, as these patients derive maximum absolute benefit 2
• Ensure all lifestyle modifications (diet, exercise, smoking cessation, blood pressure control) are optimized before adding expensive biologic therapy 2

---

Combination Therapy Strategy

The recommended stepwise approach to lipid management is: 2

1. High-intensity statin as first-line therapy
2. Add ezetimibe if LDL-C target not achieved
3. Add PCSK9 inhibitor (Praluent or evolocumab) if LDL-C remains ≥70 mg/dL in very high-risk patients or ≥100 mg/dL in severe hypercholesterolemia

This sequential intensification maximizes LDL-C reduction while minimizing costs and treatment burden. 2